ZNF862

Across TCGA pan-cancer cohorts, ZNF862 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of ZNF862’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where ZNF862 RNA is repressed in tumor relative to normal tissue. In most cancer types ZNF862 is over-expressed in tumor, although a few such as THCA and UCEC show the opposite, repressed pattern.

THCA, LIHC, and UCEC are the cancer types where ZNF862 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ZNF862 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	III,IV	−1.174	<.001	10	view →
LIHC	Female	II,III,IV	+0.989	<.001	9	view →
UCEC	All	All	−0.538	.005	6	view →
BRCA	Female	All	−0.449	<.001	6	view →
CHOL	Female	All	+2.029	<.001	5	view →
HNSC	All	All	−0.353	.006	4	view →
LUSC	Male	All	−0.307	.024	2	view →
PRAD	All	All	+0.254	.018	2	view →
ESCA	Female	All	−0.883	.045	1	view →
KICH	All	All	−0.391	.012	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

ZNF862–THCA

Open the THCA breakdown →